A 42-year-old male with type 2 diabetes mellitus presents to the emergency department with severe metabolic acidosis (pH 7.18, HCO₃⁻ 12 mmol/L, lactate 8.5 mmol/L). He has been on metformin 2000 mg daily for 3 years and has normal renal function (eGFR 75 mL/min/1.73 m²). His liver ultrasound shows mild fatty infiltration but no cirrhosis. Blood glucose is 320 mg/dL. Which of the following best explains the impaired lactate clearance in this patient?

Explanation

## Metformin-Associated Lactate Acidosis (MALA) Pathophysiology ### The Mechanism of Impaired Lactate Clearance **Key Point:** Metformin inhibits mitochondrial complex I (NADH dehydrogenase) in hepatocytes, reducing the NAD⁺/NADH ratio. This impairs lactate dehydrogenase (LDH) activity, which requires NAD⁺ as a cofactor to convert lactate → pyruvate, the first step in hepatic gluconeogenesis. ### Lactate Clearance Biochemistry The conversion of lactate to glucose requires: $$\text{Lactate} + \text{NAD}^+ \xrightarrow{\text{LDH}} \text{Pyruvate} + \text{NADH} + \text{H}^+$$ **High-Yield:** Metformin's inhibition of complex I reduces NAD⁺ regeneration, creating a NAD⁺-depleted state that shifts the equilibrium toward lactate accumulation. ### Cori Cycle Disruption in Metformin Use ```mermaid flowchart TD A["Metformin intake"]:::action --> B["Complex I inhibition"]:::action B --> C["↓ NAD⁺ regeneration"]:::urgent C --> D["LDH activity ↓"]:::urgent D --> E["Lactate → Pyruvate conversion impaired"]:::urgent E --> F["Lactate accumulation"]:::urgent F --> G["Metabolic acidosis"]:::urgent ``` ### Risk Factors for MALA in This Patient | Risk Factor | Status in This Patient | Significance | |-------------|------------------------|---------------| | **Renal impairment** | eGFR 75 (borderline) | Reduced metformin clearance | | **Hepatic dysfunction** | Fatty infiltration, no cirrhosis | Impaired gluconeogenesis | | **Hyperglycemia** | 320 mg/dL | Osmotic stress, impaired metabolism | | **Metformin dose** | 2000 mg daily | Standard dose, but cumulative effect | | **Age** | 42 years | Metabolic vulnerability | **Clinical Pearl:** MALA is rare (~3–10 cases per 100,000 metformin users per year) but has a mortality rate of 30–50%. It occurs when metformin accumulates AND hepatic lactate clearance is impaired. ### Why Lactate Accumulates 1. **Reduced NAD⁺:** Complex I inhibition → decreased NAD⁺ regeneration 2. **LDH substrate limitation:** LDH cannot function without NAD⁺ 3. **Pyruvate accumulation:** Lactate cannot be converted to pyruvate 4. **Gluconeogenesis blockade:** Pyruvate is the substrate for PEPCK and gluconeogenesis 5. **Lactate accumulation:** Lactate builds up in blood → metabolic acidosis **Mnemonic:** **MALA** = **M**etformin **A**ssociated **L**actate **A**cidosis. The mechanism is NAD⁺ depletion → LDH inhibition → lactate accumulation. ### Management Implications - **Discontinue metformin immediately** - **Supportive care:** IV fluids, mechanical ventilation if needed - **Hemodialysis:** Removes both lactate and metformin - **Sodium bicarbonate:** May be used to correct acidosis [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 297]